Jubilant Life Sciences has surged over 7% to Rs 125 after the company announced a successful resolution to U.S. food and drug administration (FDA) warning letter for Montreal facility.
The company has received a communication from the US FDA, classifying its pharmaceutical manufacturing facility at Montreal, Canada as ‘Acceptable’, Jubilant Life Sciences said in a statement.
This resolves all issues raised by the FDA on the facility in February 2013 and subsequent communications, it added.
The drug firm said, the development follows completion of FDA’s review of the Company’s responses post the February letter and the subsequent re-inspection conducted at Jubilant’s Montreal facility in September, 2013. This development successfully resolves the FDA issues at our Montreal facility.
The stock opened at Rs 123 and touched a high of Rs 126 on the BSE. A combined around 381,000 shares have changed hands on the counter so far on the BSE and NSE.
The company has received a communication from the US FDA, classifying its pharmaceutical manufacturing facility at Montreal, Canada as ‘Acceptable’, Jubilant Life Sciences said in a statement.
This resolves all issues raised by the FDA on the facility in February 2013 and subsequent communications, it added.
The drug firm said, the development follows completion of FDA’s review of the Company’s responses post the February letter and the subsequent re-inspection conducted at Jubilant’s Montreal facility in September, 2013. This development successfully resolves the FDA issues at our Montreal facility.
The stock opened at Rs 123 and touched a high of Rs 126 on the BSE. A combined around 381,000 shares have changed hands on the counter so far on the BSE and NSE.
